Suvorexant: A promising, novel treatment for insomnia

Neuropsychiatric Disease and Treatment

Volumn 12, Issue , 2016, Pages 491-495

  Lee Iannotti, Joyce K ^a   Parish, James M ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Benzodiazepan receptor antagonist; CYP3A4; Insomnia; MK 4305; Orexin receptor antagonist

Indexed keywords

GABOXADOL; SUVOREXANT; TRAZODONE; ZOLPIDEM;

AREA UNDER THE CURVE; COUGHING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; RESPIRATORY TRACT INFECTION; REVIEW; SEX DIFFERENCE; SLEEP QUALITY; SLEEP TIME; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT WITHDRAWAL; XEROSTOMIA;

EID: 84959449879     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S31495     Document Type: Review

References (20)

1. Merrigan JM, Buysse DJ, Bird JC, et al. Insomnia. JAMA. 2013;309:733.
2. American Sleep Association. About Insomnia. Available from: https://www.sleepassociation.org/patients-general-public/insomnia/insomnia/. Accessed June 1, 2015.
3. American Academy of Sleep Medicine. International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual. Chicago, IL: American Academy of Sleep Medicine; 2001.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
5. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487-504.
6. Dopp JM, Phillips BG. Sleep disorders. In: DiPiro JT, Talbert RL, Yee GC, et al. editors. Pharmacotherapy: A Pathophysiological Approach. 9th ed. New York, NY: McGraw-Hill; 2014.
7. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320-5332.
8. Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by MK-4305 - a novel dual orexin receptor antagonist. J Neurogenet. 2011;25:52-61.
9. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015.
10. Taheri S, Sunter D, Dakin C, et al. Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rate central nervous system. Neurosci Lett. 2000;279:109-112.
11. Zeitzer JM, Buckmaster CL, Parker KJ, et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci. 2003;23:3555-3560.
12. Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci. 2006;27:368-374.
13. Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for the newly approved hypnotic - what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:1429-1441.
14. Belsomra® (survorexant) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2014.
15. Herring JW, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265-2274.
16. Sun H, Kennedy WP, Darren W, et al. Effects of survorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36:259-267.
17. Michelson D, Snyder E, Pardis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double blind, placebo-controlled trial. Lancet Neurol. 2014;13:461-471.
18. US Food and Drug Administration. FDA approves new type of sleep drug, Belsomra. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm. Accessed June 2, 2015.
19. Department of Justice. Drug Enforcement Administration. Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule. Fed Regist. 2014;79:51243-51247.
20. Ma AJ, Svetnik V, Snyder E, et al. Electroencephalographic prower spectral density profile of the orexin receptor antagonist surorexant in patients with primary insomnia and healthy subjects. SLEEP. 2014;37(10):1609-1619.